Physician profile
Shahla Ali
NPI 1740505957
$51,797.90
in general payments reported to CMS, 2019-2025
40 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $7,105 · 2021: $8,752 · 2022: $16K · 2023: $15K · 2024: $1,572 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,316 · Consulting Fee: $390 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,675.00 |
| Food and Beverage | $6,316.05 |
| Consulting Fee | $390.00 |
| Education | $114.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33,723.98 | 2019-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $3,936.80 | 2019-2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $2,542.47 | 2021-2025 | Vraylar, Qulipta |
| Janssen Scientific Affairs, LLC | $1,950.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $1,312.57 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,040.26 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Corium, LLC | $738.70 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $678.43 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $600.62 | 2022-2025 | Qelbree, Qelbree |
| Johnson & Johnson Health Care Systems INC. | $585.00 | 2022 | |
| Lundbeck LLC | $562.96 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $542.36 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $477.38 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $461.39 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neos Therapeutics, LP | $295.28 | 2020-2023 | Adzenys Xr-Odt |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $267.49 | 2019-2020 | |
| Bausch Health US, LLC | $257.47 | 2019-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $221.64 | 2019-2023 | Trintellix |
| Tris Pharma INC | $187.88 | 2019-2024 | Dyanavel Xr |
| Brainsway USA INC | $184.24 | 2021 | |
| Vanda Pharmaceuticals INC. | $164.15 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $130.13 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $128.66 | 2019-2021 | |
| Indivior INC. | $88.34 | 2019-2023 | Perseris |
| Eisai INC. | $79.85 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $74.16 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $73.76 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $70.27 | 2020-2025 | Rexulti |
| Adlon Therapeutics L.P. | $64.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.76 | 2020 | |
| Idorsia Pharmaceuticals US INC | $46.58 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $43.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.98 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $36.11 | 2025 | Zurzuvae |
| Orexo US, INC. | $33.80 | 2020 | |
| Noven Therapeutics, LLC | $28.90 | 2023-2024 | Xelstrym |
| Soleno Therapeutics, INC. | $26.26 | 2025 | Vykat Xr |
| Owp Pharmaceuticals, INC. | $21.26 | 2020-2022 | |
| Avion Pharmaceuticals | $20.57 | 2023 | Methylphenidate Hydrochloride |
| Azurity Pharmaceuticals, INC. | $16.49 | 2024 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahla Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.